Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy

被引：11

作者：

Caudai, C. ^{[1
]}

Materazzi, A. ^{[2
]}

Saladini, F. ^{[2
]}

Di Giambenedetto, S. ^{[3
]}

Torti, C. ^{[4
]}

Ricciardi, B. ^{[5
]}

Rossetti, B. ^{[3
,6
]}

Almi, P. ^{[7
]}

De Luca, A. ^{[6
]}

Zazzi, M. ^{[2
]}

机构：

[1] Siena Univ Hosp, Microbiol & Virol Unit, Viale M Bracci 16, I-53100 Siena, Italy

[2] Univ Siena, Dept Med Biotechnol, Siena, Italy

[3] Univ Cattolica Sacro Cuore, Infect Dis Clin, Rome, Italy

[4] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Infect Dis Unit, Catanzaro, Italy

[5] Misericordia Hosp, Infect Dis Unit, Grosseto, Italy

[6] Siena Univ Hosp, Infect Dis Unit, Siena, Italy

[7] Siena Univ Hosp, Unit Infect Dis & Hepatol, Siena, Italy

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2018年 / 24卷 / 03期

关键词：

Direct-acting antivirals; Drug resistance; Hepatitis C virus; NS5A; Pegylated interferon-alpha and ribavirin; NAIVE PATIENTS; THERAPY; MUTATIONS;

D O I：

10.1016/j.cmi.2017.08.003

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: Genetic variability in NS5A is associated with different levels of resistance to the currently licensed NS5A inhibitors. The aim of this study was to detect NS5A inhibitor resistance associated substitutions (RASs) in hepatitis C virus (HCV) genotype 1 (GT1) patients who are naive to direct-acting HCV antivirals. Methods: Amplification, Sanger sequencing and phylogenetic analysis of the HCV NS5A region were performed on plasma obtained from 122 consecutive patients with HCV chronic infection attending four different clinics in Italy. Results: NS5A inhibitor RASs were detected in 14/61 (23.0%) HCV GT1b and 3/61 (4.9%) HCV GT1a infected patients (p 0.007). The pan-genotypic RAS Y93H was detected in 1 (1.6%) GT1a and 4 (6.6%) GT1b patients. GT1a sequences clustered into two different clades with RASs detected in 1/34 (2.9%) clade I and 2/27 (7.4%) clade II sequences. Conclusions: Although the impact of naturally occurring NS5A RASs might be limited with upcoming pan-genotypic treatment regimens, this information is still useful to map naturally occurring HCV variants in different geographic areas in the context of current HCV therapy. (C) 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

引用

页码：308.e5 / 308.e8

页数：4

共 15 条

[1] Longitudinal analysis of the 5′UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients [J].